Thus, blocking TGF-β-promoted ERK-1/2 activity might be a straightforward approach to inhibit NSCLC metastasis, in particular in patients with high RAF-1 and TGF-β levels. This evidence concerns the gene RAF1 and non-small cell lung carcinoma.